tbuckley/cabot-search huggingface dataset:
Divergent approaches in the vaccination of recently arrived migrants to Europe: a survey of national experts from 32 countries, 2017
Authors: Sally Hargreaves, Laura B Nellums, Sofanne J Ravensbergen, Jon S Friedland, Ymkje Stienstra
Journal: Eurosurveillance (2018)

Background Migrants within the European Union and European Economic Area (EU/EEA) may be underimmunised and lack documentation on previous vaccinations. We investigated approaches to vaccination in recently arrived adult and child migrants, and guideline availability and implementation. Methods : Between March and May 2017, a national vaccination expert from every EU/EEA country and Switzerland completed an electronic questionnaire. We used descriptive analyses to calculate percentages, and framework analysis to synthesise free-text responses. Results : We approached 32 countries (response rate 100%). Although 28 experts reported vaccination guidance at national level, specific guidelines for recently arrived migrants were only available in six countries and not consistently implemented. Twenty-three countries administered vaccinations during on-arrival health checks. Most experts recommended multiple vaccination opportunities be made available: at point of entry (n = 13) or at holding level (reception centres, migrant camps, detention centres) (n = 21). In 30 countries, child migrants without evidence of previous vaccination were re-vaccinated according to the national schedule. Diphtheria-pertussis-tetanus and polio vaccinations were given to migrant children in all countries, measles-mumps-rubella (MMR) in 31 countries, hepatitis B vaccination in 25. Low levels of catch-up vaccination were reported in adult migrants, with only 13 countries offering MMR and 10 countries charging fees. Conclusion : Existing guidance is often not migrant-specific and may not be applied in practice; clarification is needed on which vaccines should be given. Strategies are needed specifically for catch-up vaccination in adult migrants. Vaccinations should be offered in multiple settings, free of charge, with sufficient guidance and training provided to front-line healthcare professionals.
Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study
Authors: H.-J. Chang, Y.-F. Chiu, J.-S. Chen, C.-P. Li, C.-L. Ho, Y.-M. Shyr, W.-C. Chiou, C.-N. Yeh, R.-K. Hsieh, Y.-L. Lin, Y.-W. Tien, T.-L. Hwang, Y.-S. Shan, L.-T. Chen
Journal: Annals of Oncology (2018)
GW29-e0805 Study on the mechanism of Pulsatilla Radixtreated in treating Heart Failure by network pharmacology
Authors: Huimin Zhang, Yinglu Ren, Jinying Liu, Congping Su, Qing Wang, Xuan Xie, Lei Tian, Wei Wang, Shuzhen Guo
Journal: Journal of the American College of Cardiology (2018)
Administration of ferrous sulfate drops has significant effects on the gut microbiota of iron-sufficient infants: a randomised controlled study
Authors: Kotryna Simonyté Sjödin, Magnus Domellöf, Carina Lagerqvist, Olle Hernell, Bo Lönnerdal, Ewa A Szymlek-Gay, Andreas Sjödin, Christina E West, Torbjörn Lind
Journal: Gut (2018)

Administration of ferrous sulfate drops has significant effects on the gut microbiota of iron-sufficient infants: a randomised controlled studyWe read with interest the work by Jaeggi et al 1 and Paganinni et al 2 and commend their efforts.Despite differences in iron concentration, infants' age and sequencing techniques, both studies demonstrate unfavourable iron effects on gut microbiota with decreased abundance of bifidobacteria and lactobacillus, and increased abundance of pathogenic bacteria in iron-deficient/anaemic Kenyan infants.
Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series
Authors: Javier Narváez, Judit LLuch, Juan José Alegre Sancho, Maria Molina-Molina, Joan Miquel Nolla, Ivan Castellví
Journal: Annals of the Rheumatic Diseases (2018)

Adverse eventsYes herpeszoster: 1; bacterial infections: 3, needing hospitalisation in one of them (osteomyelitis).
Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
Authors: Sheridan M. Hoy
Journal: Drugs (2018)

Sodium zirconium cyclosilicate (Lokelma™) [hereafter referred to as SZC] is a non-absorbed, non-polymer zirconium silicate compound that preferentially exchanges hydrogen and sodium for potassium and ammonium ions in the gastrointestinal tract (GIT), thereby increasing faecal potassium excretion and lowering serum potassium levels. It is available as a powder for oral suspension (in water) and is approved in the EU and the USA for the treatment of hyperkalaemia in adults. In two multinational, phase III studies in adults with hyperkalaemia, SZC 10 g three times daily lowered serum potassium levels to within the normal range (3.5–5.0 mmol/L) during the first 48 h of treatment, and SZC 5 and 10 g once daily maintained normokalaemia over ≤ 28 days’ therapy. These beneficial effects were consistent across all patient subgroups (e.g. chronic kidney disease, diabetes, heart failure, concomitant use of RAAS inhibitor therapy), and appeared to be maintained over the longer term (≤ 12 months). SZC was generally well tolerated in adults with hyperkalaemia. Its tolerability profile was generally similar to that seen with placebo over ≤ 28 day, and its safety profile appeared to remain consistent over the longer term (≤ 12 months). Moreover, the incidence of hypokalemia was low. Current evidence indicates that SZC is a promising therapy for the management of hyperkalaemia in adults.
How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool “Onco’nect®”
Authors: M. Belhadj, E. Kempf, A. Lebel, A. Guillemin, H. Boussion, C. Joly, I. Baumgaertner, E. Assaf, C. Saldana, B.J.-C. Rousseau, C. Tournigand
Journal: Annals of Oncology (2018)
Limiting Elective Delivery Prior to 39 Weeks May Be Producing Harm Rather Than Benefit
Authors: James M. Nicholson, Lisa C. Kellar, Jerome L. Yaklic
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Abstract 14937: Depressive Symptoms Were Not Associated With Cardiac Event-free Survival in Heart Failure Patients With Adequate Intake of Vitamin D
Authors: Eun Kyeung Song, Seok-Min Kang, Debra K Moser, Terry A Lennie
Journal: Circulation (2015)

Introduction. Low levels of vitamin D and severe depressive symptoms have been associated with increased proinflammatory cytokines that predict cardiovascular disease. However, little is known about the relationships among depressive symptoms, vitamin D deficiency, and cardiac events in patients with heart failure (HF). Hypothesis. We hypothesized that the link of depressive symptoms to cardiac event-free survival would differ between patients with vitamin D adequacy and deficiency. Methods. A total of 232 patients with HF (age 66±8 years, 34% female) completed the Patient Health Questionnaire-9 to assess depressive symptoms and were split into 2 groups using the standard PHQ-9 cutoff point of 10. Nutrition Analysis program was used to determine average daily intake of vitamin D through a 3-day food diary. Patients with &gt; 85% probability of deficiency were defined as having a diet deficient in vitamin D. Covariate data on age, gender, body mass index, NYHA class, ejection fraction, comorbidities, and prescribed medications were obtained from review of medical records. Patients were followed for 2 years to determine time to first event of hospitalization or death. Hierarchical Cox proportional regression was used to examine our hypothesis. Results. 106 patients (46%) had depressive symptoms and 116 patients (50%) had vitamin D deficiency. During 2 years, 88 patients (38%) were hospitalized or died due to cardiac problems. Depressive symptoms were associated with vitamin D deficiency ( X 2 =4.45, p = .035). In patients with vitamin D deficiency, depressive symptoms (HR=2.56, 95% CI=1.28-5.21) predicted shorter event-free survival after controlling for all covariates, whereas there was no difference in cardiac event-free survival between patients with depressive symptoms and no depressive symptoms in patients with vitamin D adequacy ( p = .185) . Conclusions. The data suggest that depressive symptoms were not associated with cardiac event-free survival in HF patients with adequate intake of vitamin D. Future study is required to determine whether vitamin D adequacy could play a protective role in the impact of depressive symptoms on cardiac event-free survival in patients with HF.
Abstract 17939: Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease: Results From TRACER
Authors: Schuyler Jones, Pierluigi Tricoci, Zhen Huang, David J Moliterno, Robert A Harrington, Peter Sinnaeve, John Strony, Frans Van de Werf, Harvey D White, Claes Held, Paul W Armstrong, Philip E Aylward, Edmond Chen, Manesh R Patel, Kenneth W Mahaffey
Journal: Circulation (2013)

Background: In TRACER, vorapaxar, a PAR-1 antagonist, added to standard of care in non-ST-segment elevation acute coronary syndrome (NSTE ACS) patients modestly reduced ischemic events but signific...
Abstract 12215: Comparison of Clinical Outcome Between DES Implantation and DCB Angioplasty in Patients With LMB-ISR Lesions
Authors: Hyung Joon Joo, Han Saem Jeong, Hyungdon Kook, Seung Hun Lee, Jae Hyoung Park, Soon Jun Hong, Cheol Woong Yu, Do-Sun Lim
Journal: Circulation (2017)

Introduction: The current guideline recommended both repeat stenting (within drug-eluting stent (DES) or bare metal stent) and drug-coated balloon (DCB) for in-stent restenosis (ISR) lesions, if te...
Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial
Authors: D.J. George, A.J. Pantuck, R. Figlin, B. Escudier, S. Halabi, M. Casey, X. Lin, L. Serfass, M.J. Lechuga Frean, A. Ravaud
Journal: Annals of Oncology (2018)
Extracellular matrix of normal brain tissue is affected by temozolomide during anti-glioblastoma treatment
Authors: A. Tsidulko, C. Bezier, G. de La Bourdonnaye, A.V. Suhovskih, G. Kazanskaya, S. Aidagulova, E.V. Grigorieva
Journal: Annals of Oncology (2018)
Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study
Authors: Richard James Partington, Sara Muller, Toby Helliwell, Christian D Mallen, Alyshah Abdul Sultan
Journal: Annals of the Rheumatic Diseases (2018)

Objective Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in older people. Contemporary estimates of the incidence and prevalence are lacking, and no previous study has assessed treatment patterns at a population level. This study aims to address this. Methods We extracted anonymised electronic medical records of patients over the age of 40 years from the Clinical Practice Research Datalink in the period 1990–2016. The absolute rate of PMR per 100 000 person-years was calculated and stratified by age, gender and calendar year. Incidence rate ratios were calculated using a Poisson regression model. Among persons with PMR, continuous and total duration of treatment with glucocorticoids (GC) were assessed. Results 5 364 005 patients were included who contributed 44 million person-years of follow-up. 42 125 people had an incident diagnosis of PMR during the period. The overall incidence rate of PMR was 95.9 per 100 000 (95% CI 94.9 to 96.8). The incidence of PMR was highest in women, older age groups and those living in the South of England. Incidence appears stable over time. The prevalence of PMR in 2015 was 0.85 %. The median (IQR) continuous GC treatment duration was 15.8 (7.9–31.2) months. However, around 25% of patients received more than 4 years in total of GC therapy. Conclusions The incidence rates of PMR have stabilised. This is the first population-based study to confirm that a significant number of patients with PMR receive prolonged treatment with GC, which can carry significant risks. The early identification of these patients should be a priority in future research.
Bone Marrow–Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence‐Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein–Interferon‐β Feedback Loop
Authors: Lin Gao, Anna K. Bird, Nida Meednu, Kristin Dauenhauer, Jane Liesveld, Jennifer Anolik, R. John Looney
Journal: Arthritis & Rheumatology (2017)

Bone marrow-derived mesenchymal stem cells (BM-MSCs) create a special microenvironment for hematopoiesis and immunity and display robust immunomodulatory properties that are impaired in systemic lupus erythematosus (SLE). This study was undertaken to identify the mechanisms of defects in human SLE BM-MSCs.
P3.09-25 Survival Analysis in Young Adults with Lung Carcinoma
Authors: J. Nicolau, M.A. Koike Folgueira, R. Roela, S. Maistro, M.L. Katayama, J. Eluf Neto, C. Luizaga, K. Ribeiro, G. De Castro
Journal: Journal of Thoracic Oncology (2018)
Abstract 12344: Mismatch Between Objectively Measured Fluid Retention and Symptoms in Patients With Heart Failure
Authors: Barbara Riegel, Victoria V Dickson, Christopher S Lee, Marguerite Daus, Julia Hill, Solim Lee, Foster Baah, Megan Streur, Elliane Irani, Lisa Rathman, Joyce W Wald, Linda Ruppert, Daniel Schwartz, Alfred Bove
Journal: Circulation (2017)

Heart failure (HF) patients are frequently hospitalized because of symptoms of congestion. Fluid accumulation is a slow process and early symptoms are often unrecognized for reasons that are unclea...
Acquired chemoresistance of colorectal cancer (CRC) cells is accompanied by pro-invasive VEGF-signaling that can be attenuated by aflibercept
Authors: A.K. Larsen, P. van Dreden, B. Chibaudel, A. de Gramont, G. Gerotziafas, S. Thouroude
Journal: Annals of Oncology (2018)
Abstract 20556: Randomized Controlled Trial of Vitamin D Adjunct Therapy for African American Patients With Left Ventricular Hypertrophy
Authors: Phillip D Levy, Aaron Brody, Tao Li, Rachelle Dawood, Lynn Marie Mango, Laura Gowland, Michael Twiner, Greg Gandits, Kenneth Svendsen, Cheryl Courage, John Flack
Journal: Circulation (2017)

Introduction: Left ventricular hypertrpophy (LVH) is a consequence of uncontrolled hypertension (HTN). Vitamin D helps regulate multiple, cardiac neurohormonal pathways, and its deficiency may cont...
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Authors: A. Friedlaender, A. Vuillemier, V. Viassolo, A. Ayme, S. De Talhouet, J.-D. Combes, J. Peron, A. Bodmer, S. Giraud, A. Buisson, V. Bonadona, I. Gauchat-Bouchardy, O. Tredan, P. Chappuis, S.I. Labidi-Galy
Journal: Annals of Oncology (2018)
Should we consider altering our patterns of care for elderly sarcoma patients?
Authors: S. Vari, C. Zoccali, V. Anelli, A. Annovazzi, M.G. Petrongari, G. Maggi, D. Giannarelli, N. Salducca, L. Favale, M. Zeuli, R. Biagini, A. Latini, W. Faltyn, M. Anza, R. Covello, J. Baldi, D. Pellegrini, E. Checcucci, F. Cognetti, V. Ferraresi
Journal: Annals of Oncology (2018)
Simulation-Based Clinical Rehearsals as a Method for Improving Patient Safety
Authors: Jennifer Arnold, Melissa Cashin, Oluyinka O. Olutoye
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Marine sponges of the genus Stelletta as promising drug sources: chemical and biological aspects
Authors: Qihao Wu, Bastien Nay, Min Yang, Yeke Ni, Hong Wang, Ligong Yao, Xuwen Li
Journal: Acta Pharmaceutica Sinica B (2018)

Marine sponges of the genus Stelletta are well known as rich sources of diverse and complex biologically relevant natural products, including alkaloids, terpenoids, peptides, lipids, and steroids. Some of these metabolites, with novel structures and promising biological activities, have attracted a lot of attention from chemists seeking to perform their total synthesis in parallel to intensive biological studies towards new drug leads. In this review, we summarized the distribution of the chemically investigated Stelletta sponges, the isolation, synthesis and biological activities of their secondary metabolites, covering the literature from 1982 to early 2018.
Interaction between B-cell activation factor and methotrexate impacts immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis
Authors: Jin Kyun Park, Ye Ji Lee, Samuel Bitoun, Kevin L Winthrop, Yunhee Choi, Eun Bong Lee, Xavier Mariette
Journal: Annals of the Rheumatic Diseases (2018)

Methotrexate (MTX) with its proven efficacy and safety profile remains as the anchor drug for the treatment of rheumatoid arthritis (RA).1 2 However, the impact of MTX alone or in conjunction with antitumour necrosis factor (anti-TNF) on humoral immune system and infection risk varies markedly among patients with RA, suggesting that other host factors influence the therapeutic response to MTX and/or anti-TNF treatment.3 A possible candidate is B-cell activating factor (BAFF), which promotes B-cell activation and differentiation for antibody production.4 When patients with RA received anti-TNF treatment, a high BAFF serum level prevented formation of antidrug antibody in patients taking MTX but not those who did not.5 Thus, in the presence of MTX, BAFF may exert a paradoxical anti-inflammatory effect. Here, we investigated whether high BAFF levels negatively impact vaccine response via the inhibitory BAFF–MTX interaction in patients with RA taking MTX.

Patients with RA according to the revised 1987 American College of Rheumatology from the randomised controlled trial (ClinicalTrials.gov identifier: NCT02897011) that aimed to investigate the effects of a 2-week MTX discontinuation on vaccine response to seasonal influenza vaccination were included in this study.6 Patients with RA were randomised to continue MTX or to hold …
PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors
Authors: D.D. Karp, D.R. Camidge, J.R. Infante, T.D. Ames, J.M. Jimeno, A.H. Bryce
Journal: Annals of Oncology (2018)

Background: PT-112, a novel platinum pyrophosphate agent under development in solid tumors and hematological malignancies, is a potent inducer of damage associated molecular patterns (DAMPs) characteristic of ICD. It also affects G1/S cell cycle transition independent of DNA damage or repair pathways. Here we present a clinical update and analysis of single-agent activity in heavily pre-treated pts. Methods: We treated 62 pts in an all-comer 3x3 Phase I dose escalation study. PT-112 was given IV for 1hr on days 1,8,15 (28d cycle) at dose levels 12 – 420 mg/m2. Results: All dose levels completed were deemed safe, with dose-linear pharmacokinetics, and MTD was not reached. Fatigue was the most common side effect. No significant acute neurotoxicity was reported in 533 infusions. Grade 1-2 peripheral neuropathy was seen in 8/62 pts (13%), and Grade 3 in 2 pts (3%) with cumulative doses of 3.1 and 4.3 g/m2. Neutropenia (6 pts) and thrombocytopenia (8 pts) were limited with no infections or bleeding. Median prior lines of therapy = 5. Tumor control, metabolic and biomarker responses were observed at doses at / above 125 mg/m2, with PSA reduction in 4 / 8 prostate pts. A non small cell lung cancer pt previously unresponsive to anti-PD-1 immunotherapy achieved a 6+ month RECIST PR at 250 mg/m2 and complete PET response in liver / bone sites. A small cell lung pt who rapidly progressed on CTLA4 + PD-1 immunotherapy achieved PR at 360mg/m2, progression free at 7.5 months. Marked tumor reduction at 360 mg/m2 is ongoing after 6 mos. in a malignant thymoma pt with bulky thoracic disease. Time to response was 5-8 wks in all 3 pts. PFS at 6 mos. was reached in 8 / 46 evaluable pts at / above 125 mg/m2 (17.4%). The ORR in 28 evaluable pts at / above 250mg/m2 was 10.7%. At the provisional RP2D, now under confirmation (360 mg/m2), 2 of 3 pts experienced durable tumor shrinkage. Conclusions: PT-112 is a novel ICD inducing agent that is safe and well tolerated. Single-agent activity occurred in heavily pre-treated pts. Neither acute neurotoxicity nor kidney damage occurred. Fatigue was the most common side effect. Beneficial activity was observed at a range of doses, indicative of a broad therapeutic index, lack of cross-resistance with standard agents and feasibility for combinations. Clinical trial identification: NCT: 2266745 IND: 118577. Legal entity responsible for the study: Phosplatin Therapeutics LLC. Funding: Phosplatin Therapeutics LLC. Disclosure: D.D. Karp: Member of the scientific advisory board: Phosplatin Therapeutics. T.D. Ames, J.M. Jimeno: Employee and part owner: Phosplatin Therapeutics. All other authors have declared no conflicts of interest.
GP trainees recruited in England surpass target
Authors: Abi Rimmer
Journal: BMJ (2018)

The number of doctors entering GP training in England this year has surpassed the target set by Health Education England (HEE) by more than 200.

HEE said that 3473 trainees were starting their GP training this year (beginning either in August 2018 or February 2019), compared with a recruitment target of 3250. Figures show that 3039 doctors entered GP training in England last year, so this year’s figures represent a 14% increase.1 …
Sequencing of KRAS and NRAS in 1501 colorectal carcinomas reveals significant share of mutations, which are not included in common diagnostic kits
Authors: E.N. Imyanitov, N.V. Mitiushkina, E.S. Kuligina, M. Holmatov, G.A. Yanus, I. Demidova, T. Kekeeva, M. Gordiev, E. Kharitonova, I. Tsimafeyeu, S. Tjulandin
Journal: Annals of Oncology (2018)
Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: Results from Russian Heredetary Oncogenomics project
Authors: M. Gordiev, L.H. Shigapova, O. Brovkina, R.F. Enikeev, M. Druzhkov, A. Nikitin, E. Shagimardanova, O. Gusev
Journal: Annals of Oncology (2018)